NCT04859166: Organoids lung

Prospective Primary Human Lungcancer Organoids to Predict Treatment Response

Completed Last updated 15 March 2023

What this trial tests

trial testing Organoids in Lung Cancer in 10 participants. Completed in 1 October 2022.

Timeline

15 November 2017

Primary endpoint
1 October 2022

1 October 2022

Quick facts

Lead sponsor	Maastricht Radiation Oncology
Status	Completed
Study type	OBSERVATIONAL
Enrollment	10
Start date	15 November 2017
Primary completion	1 October 2022
Estimated completion	1 October 2022
Sites	2 locations across Netherlands

Drugs / interventions tested

• Organoids

Conditions studied

• Lung Cancer — all drugs for Lung Cancer →

Sponsor

Maastricht Radiation Oncology — full company profile →

Who can join

Eligibility, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Organoids are generated from tumor biopsies, taken during a standard procedure. and are a collection of organ-specific cell types that are able to self-organize in-vitro in a manner similar to the in-vivo situation (3D). They have the capability to facilitate in-depth analysis of patient's own tumor material at point of diagnosis and during progressive/recurrent disease. There is currently no published protocol to establish long-term lung cancer organoids from lung cancer patients. Such a methodology would enable the prospective identification of 'patient tailored optimal treatments" as well as the derivation of predictive biomarkers for response and relapse. Apart from organoids, xenograft models also still have their merits. To generate PDX, tumor material will be retrieved from surgical specimens, cut in small pieces, transplanted in the recipient immune deficient animals either subcutaneously or implanted directly into the lung. A tumor with the median growth rate will be serially transplanted in vivo for further therapeutic experiments. Dedicated small animal irradiaton in our facility enables precise local irradiation of lung tumors with minimal radiation exposure of the surrounding normal tissues. Integrated cone beam computed tomography imaging system allows longitudinal monitoring of tumor response to novel treatments.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Organoids: The current status and biomedical applications.
   Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274
2. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.
   Zhou Z, Cong L, Cong X. · · 2021 · cited 112× · PMID 35036354 · DOI 10.3389/fonc.2021.762184
3. Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.
   Bi J, Newtson AM, Zhang Y, Devor EJ, et al · · 2021 · cited 57× · PMID 34200645 · DOI 10.3390/cancers13122901
4. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
   Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
5. The application of patient-derived organoid in the research of lung cancer.
   Li Y, Gao X, Ni C, Zhao B, et al · · 2023 · cited 29× · PMID 36696006 · DOI 10.1007/s13402-023-00771-3
6. Lung Organoids-The Ultimate Tool to Dissect Pulmonary Diseases?
   Bosáková V, De Zuani M, Sládková L, Garlíková Z, et al · · 2022 · cited 25× · PMID 35912110 · DOI 10.3389/fcell.2022.899368
7. Scientific Validation and Clinical Application of Lung Cancer Organoids.
   Lee D, Kim Y, Chung C. · · 2021 · cited 24× · PMID 34831235 · DOI 10.3390/cells10113012
8. Lung Cancer Organoids: The Rough Path to Personalized Medicine.
   Rossi R, De Angelis ML, Xhelili E, Sette G, et al · · 2022 · cited 21× · PMID 35954367 · DOI 10.3390/cancers14153703